In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
21 Aug 2021
Historique:
received: 30 06 2021
accepted: 16 08 2021
entrez: 22 8 2021
pubmed: 23 8 2021
medline: 15 1 2022
Statut: epublish

Résumé

Inhaled epoprostenol (iEPO) has been shown to reduce pulmonary artery pressure and improve oxygenation. iEPO is mainly delivered via a syringe pump with feed tubing connected to a vibrating mesh nebulizer with high or low formulation concentration delivery. An in vitro study and a two-period retrospective case-control study were implemented. The in vitro study compared iEPO delivery via invasive ventilation at low concentrations of 7.5, and 15 mcg/mL and high concentration at 30 mcg/mL, to deliver the ordered dose of 30 and 50 ng/kg/min for three clinical scenarios with predicted body weight of 50, 70 and 90 kg. While in the clinical study, adult patients receiving iEPO via invasive ventilation to treat refractory hypoxemia, pulmonary hypertension, or right ventricular failure were included. 80 patients received low concentration iEPO at multiple concentrations (2.5, 7.5, and 15 mcg/mL, depending on the ordered dose) from 2015 to 2017, while 84 patients received high concentration iEPO at 30 mcg/mL from 2018 to 2019. In the in vitro study, there were no significant differences in aerosol deposition between high vs low concentrations of iEPO at a dose of 50 ng/kg/min. In the clinical study, age, gender, ethnicity, and indications for iEPO were similar between high and low concentration groups. After 30-120 min of iEPO administration, both delivery strategies significantly improved oxygenation in hypoxemic patients and reduced mean pulmonary arterial pressure (mPAP) for patients with pulmonary hypertension. However, no significant differences of the incremental changes were found between two delivery groups. Compared to low concentration, high concentration delivery group had better adherence to the iEPO weaning protocol (96% vs 71%, p < 0.001), fewer iEPO syringes utilized per patient (5 [3, 10] vs 12 [6, 22], p = 0.001), and shorter duration of invasive ventilation (6 [3, 12] vs 9 [5, 18] days, p = 0.028). Intensive care unit length of stay and mortality were similar between two groups. Compared to low concentration delivery of iEPO, high concentration iEPO via a vibrating mesh nebulizer maintained clinical benefits and increased clinician compliance with an iEPO weaning protocol, required less medication preparation time, and shortened duration of invasive ventilation.

Sections du résumé

BACKGROUND BACKGROUND
Inhaled epoprostenol (iEPO) has been shown to reduce pulmonary artery pressure and improve oxygenation. iEPO is mainly delivered via a syringe pump with feed tubing connected to a vibrating mesh nebulizer with high or low formulation concentration delivery.
METHODS METHODS
An in vitro study and a two-period retrospective case-control study were implemented. The in vitro study compared iEPO delivery via invasive ventilation at low concentrations of 7.5, and 15 mcg/mL and high concentration at 30 mcg/mL, to deliver the ordered dose of 30 and 50 ng/kg/min for three clinical scenarios with predicted body weight of 50, 70 and 90 kg. While in the clinical study, adult patients receiving iEPO via invasive ventilation to treat refractory hypoxemia, pulmonary hypertension, or right ventricular failure were included. 80 patients received low concentration iEPO at multiple concentrations (2.5, 7.5, and 15 mcg/mL, depending on the ordered dose) from 2015 to 2017, while 84 patients received high concentration iEPO at 30 mcg/mL from 2018 to 2019.
RESULTS RESULTS
In the in vitro study, there were no significant differences in aerosol deposition between high vs low concentrations of iEPO at a dose of 50 ng/kg/min. In the clinical study, age, gender, ethnicity, and indications for iEPO were similar between high and low concentration groups. After 30-120 min of iEPO administration, both delivery strategies significantly improved oxygenation in hypoxemic patients and reduced mean pulmonary arterial pressure (mPAP) for patients with pulmonary hypertension. However, no significant differences of the incremental changes were found between two delivery groups. Compared to low concentration, high concentration delivery group had better adherence to the iEPO weaning protocol (96% vs 71%, p < 0.001), fewer iEPO syringes utilized per patient (5 [3, 10] vs 12 [6, 22], p = 0.001), and shorter duration of invasive ventilation (6 [3, 12] vs 9 [5, 18] days, p = 0.028). Intensive care unit length of stay and mortality were similar between two groups.
CONCLUSION CONCLUSIONS
Compared to low concentration delivery of iEPO, high concentration iEPO via a vibrating mesh nebulizer maintained clinical benefits and increased clinician compliance with an iEPO weaning protocol, required less medication preparation time, and shortened duration of invasive ventilation.

Identifiants

pubmed: 34419068
doi: 10.1186/s12931-021-01827-4
pii: 10.1186/s12931-021-01827-4
pmc: PMC8379597
doi:

Substances chimiques

Antihypertensive Agents 0
Reagent Kits, Diagnostic 0
Epoprostenol DCR9Z582X0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

231

Informations de copyright

© 2021. The Author(s).

Références

J Intensive Care Med. 2021 Mar;36(3):327-333
pubmed: 33234007
Crit Care. 2020 Aug 17;24(1):506
pubmed: 32807226
Am J Health Syst Pharm. 2019 Sep 3;76(18):1413-1419
pubmed: 31372630
Anesth Analg. 2017 Aug;125(2):393-402
pubmed: 28598920
Ann Pharmacother. 2018 Oct;52(10):956-964
pubmed: 29749260
J Intensive Care Med. 2021 Apr;36(4):466-476
pubmed: 32133901
Respir Care. 2013 Aug;58(8):1315-22
pubmed: 23232732
Cochrane Database Syst Rev. 2017 Jul 24;7:CD007733
pubmed: 28806480
Respir Care. 2017 Nov;62(11):1387-1395
pubmed: 28720675
Pediatr Pulmonol. 2020 Feb;55(2):322-329
pubmed: 31782914
Crit Care Explor. 2020 Dec 16;2(12):e0307
pubmed: 33354678
Ann Pharmacother. 2018 Dec;52(12):1173-1181
pubmed: 29890848
Pharmaceutics. 2019 Jun 14;11(6):
pubmed: 31207936
J Clin Med. 2020 Feb 07;9(2):
pubmed: 32046152
Respir Care. 2015 Jun;60(6):794-802; discussion 802-5
pubmed: 26070575
Ann Pharmacother. 2020 May;54(5):434-441
pubmed: 31729256
Anesth Analg. 1999 Sep;89(3):650-1
pubmed: 10475298
Chest. 2015 Jun;147(6):1510-1522
pubmed: 25742022

Auteurs

Jie Li (J)

Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, 600 S Paulina St, Suite 765, Chicago, IL, 60612, USA. Jie_Li@rush.edu.

Ashley E Augustynovich (AE)

Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, 600 S Paulina St, Suite 765, Chicago, IL, 60612, USA.

Payal K Gurnani (PK)

Department of Pharmacy, Rush University Medical Center, Chicago, IL, USA.

James B Fink (JB)

Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, 600 S Paulina St, Suite 765, Chicago, IL, 60612, USA.
Aerogen Pharma Corp, San Mateo, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH